Mendus
5.07 SEK
-0.39 %
Less than 1K followers
IMMU
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.39 %
-10.42 %
-26.73 %
-30.45 %
-35.01 %
-41.05 %
-90.59 %
-96.43 %
-96.17 %
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
Read moreMarket cap
317.3M SEK
Turnover
39.41K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
11/2
2026
Annual report '25
8/5
2026
General meeting '26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Kommuniké från extra bolagsstämma i Mendus AB (publ) den 16 december 2025
Mendus Announces Summary of Data Presented at ASH
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
